Exelixis, Inc.

Founded in 1994, Exelixis, Inc. (Nasdaq: EXEL) is a commercially successful, oncology-focused biotechnology company that strives to accelerate the discovery, development and commercialization of new medicines for difficult-to-treat cancers. Following early work in model genetic systems, we established a broad drug discovery and development platform that has served as the foundation for our continued efforts to bring new cancer therapies to patients in need. We discovered our lead compounds, cabozantinib and cobimetinib, and advanced them into clinical development before entering into partnerships with leading biopharmaceutical companies in our efforts to bring these medicines to patients globally. We are steadfast in our commitment to prudently reinvest in our business to maximize the potential of our pipeline. 

Bank Name Exelixis, Inc.
Stock Exchange NASDAQ
Symbol EXEL
Sector Healthcare
Industry Biotechnology: Commercial Physical
Country United States
World Region America
Chairman Dr. Stelios Papadopoulos
CEO Dr. Michael M. Morrissey
Employees 372
Website www.endologix.com
Registered Year 1992